Advances in Biomarker Testing Drives Cancer Management to Soon Resemble Chronic Disease Management, Finds Frost & Sullivan

Advances in Biomarker Testing Drives Cancer Management to Soon Resemble Chronic Disease Management, Finds Frost & Sullivan PR Newswire MOUNTAIN VIEW, California, Sept. 25, 2012 - Health plans require clear evidence of the clinical utility of biomarker tests MOUNTAIN VIEW, California, Sept. 25, 2012 /PRNewswire/ -- With technological advances in diagnostics, physicians may shortly have real-time information about the tumor at various stages of patient management. Future cancer biomarker tests will also be multiplexed and comprise multiple biomarker types. As personalized medicine involves matching effective treatments to individuals based on their genetic disposition and other reliable factors, highly specific biomarkers are critical for identifying likely responders from non- responders. New analysis from Frost & Sullivan's (http://www.healthcare.frost.com/) Analysis of the U.S. Cancer Biomarker Testing Market research finds that the health plan reimbursement market earned revenues of $7.86 billion in 2011 and estimates this to reach $11.46 billion in 2017. If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.